Evonetix is pioneering a transformative approach to gene synthesis, aiming to democratize access to high-quality, gene-length DNA for researchers. Their innovative technology seeks to establish a "gene foundry" in every laboratory, significantly enhancing the speed and scale of DNA synthesis. By reimagining traditional methods, Evonetix addresses the limitations of current gene synthesis approaches, which are often slow, costly, and prone to inaccuracies. Their vision includes the capability to produce gene-length DNA in just three days, thereby accelerating the design-build-test cycle for critical applications such as vaccines, therapeutics, and proteins.

In collaboration with Analog Devices, Evonetix is developing a semiconductor-based gene synthesis platform that promises to revolutionize the field of synthetic biology. This partnership focuses on creating a turn-key solution that integrates advanced thermal control for DNA synthesis, enhancing productivity by up to tenfold. The joint efforts aim to overcome existing bottlenecks in DNA production, enabling faster and more efficient development of biologic therapies. With this technology, Evonetix is poised to significantly impact healthcare and other sectors by providing researchers with the tools necessary to harness the full potential of engineering biology.

United Kingdom

Evonetix is set to revolutionizede novogene synthesis to facilitate the fast-growing and exciting field of synthetic biology.The company's unique selling point is driven by high fidelity and parallelization of gene synthesis.Evonetix's technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of 10,000 miniaturized reaction sites, allowing massive parallelism in the DNA synthesis process and therefore very high throughput.

Evonetix

Company Details